New drug duo targets tough lung cancer mutation
Disease control
Completed
This study tested whether combining two drugs, sotorasib and RMC-4630, could help people with a specific type of advanced lung cancer (KRASG12C mutation) after their standard treatments stopped working. It involved 47 adults to see if the combination could shrink tumors and was s…
Phase: PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Apr 02, 2026 04:12 UTC